Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 5/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 5/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793448 | 0.79 | BRD4 (0.36) | BRD4DHODHBUB1GSK3BPIM1 | |
| SCHEMBL4158608 | 0.73 | CDK2 (0.52) | — | |
| SCHEMBL4271434 | 0.72 | PIM1 (0.38) | BRD4PIM1PIM2 | |
| SCHEMBL6787179 | 0.72 | LMNA (0.38) | — | |
| SCHEMBL5229161 | 0.70 | CDK2 (0.54) | EP300CREBBPBRD4FLT3 | |
| SCHEMBL5227170 | 0.70 | GRM4 (0.42) | EP300CREBBPBRD4PIM1PIM2 | |
| SCHEMBL5226915 | 0.69 | CDK2 (0.56) | EP300CREBBPBRD4 | |
| SCHEMBL6791545 | 0.68 | SIGMAR1 (0.31) | — | |
| SCHEMBL4150539 | 0.67 | CDK2 (0.51) | — | |
| SCHEMBL4450382 | 0.67 | PIM1 (0.37) | BRD4PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478357-B1 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-01-31 | — | — | EP | claimed |
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-11 | — | — | US | claimed |
| EP-1478357-A2 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2004-11-24 | — | — | EP | claimed |
| WO-2003070236-A2 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2003-08-28 | — | — | WO | claimed |
| EP-1478357-B1 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-01-31 | — | — | EP | disclosed |
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-11 | — | — | US | disclosed |
| EP-1478357-A2 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003070236-A2 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | TP53, NFATC1, MAP3K15 | EP300 643/4885CREBBP 460/4885BRD4 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.